HR and triple-negative breast carcinoma: Grade 1 disease was present in 8.5% of patients, grade 2 in 35.5%, and grade 3 in 53.4%; 25.1% had human epidermal growth factor receptor 2 (HER2)–positive, 74.6% had hormone receptor (HR)+, and 16.6% had triple-negative breast cancer.